Both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have launched formal safety reviews after receiving hundreds of adverse event reports
Loss of TGH/Ces3 in mice decreases blood lipids, improves glucose tolerance, and increases energy expenditure
A large study of people with type 2 diabetes suggests that those who started treatment with a glucagonlike peptide (GLP)1 receptor agonist after diagnosis had slightly increased risk of developing a serious eye condition called ischemic optic neuropathy than people with diabetes treated with other medications
Geraniin inhibits whole blood IFN- and IL-6 and promotes IL-1 and IL-8, and stimulates calcium-dependent and sucrose-sensitive erythrocyte death
FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products
For the purchase decision framework, see Buy BPC-157 in Canada: The Complete Due Diligence Buyer's Guide